Is it time for a new yellow fever vaccine?

Vaccine

Volumn 28, Issue 51, 2010, Pages 8073-8076

  Hayes, Edward B ^a  

^a CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

Author keywords

Flavivirus vaccine; Global health; Traveler's health; Yellow fever; Yellow fever vaccine

Indexed keywords

INACTIVATED VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; POLIOMYELITIS VACCINE; YELLOW FEVER VACCINE;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ADVERSE OUTCOME; ANAPHYLAXIS; ANTIBODY PRODUCTION; ANTIBODY TITER; CONGENITAL INFECTION; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG UTILIZATION; ENCEPHALITIS; EXPERIMENTAL MONKEY; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; MENINGITIS; MULTIPLE ORGAN FAILURE; MYELITIS; NEUROPATHY; NONHUMAN; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; VACCINATION; VACCINE ASSOCIATED PARALYTIC POLIOMYELITIS; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS; YELLOW FEVER VACCINE ASSOCIATED VISCEROTROPIC DISEASE;

HUMANS; VACCINES, ATTENUATED; VACCINES, INACTIVATED; YELLOW FEVER VACCINE;

EID: 78649637509     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.015     Document Type: Review

References (33)

1. Monath T., Cetron M., Teuwen D. Yellow fever vaccine. Vaccines 2008, 959-1055. Saunders Elsevier. 5th ed.
2. Barrett A.D.T., Teuwen D.E. Yellow fever vaccine-how does it work and why do rare cases of serious adverse events take place?. Curr Opin Immunol 2009, 21(3):308-313.
3. Vasconcelos P.F., Luna E.J., Galler R., Silva L.J., Coimbra T.L., Barros V.L., et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001, 358(9276):91-97.
4. Martin M., Tsai T.F., Cropp B., Chang G.J., Holmes D.A., Tseng J., et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001, 358(9276):98-104.
5. Chan R.C., Penney D.J., Little D., Carter I.W., Roberts J.A., Rawlinson W.D. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 2001, 358(9276):121-122.
6. Hayes E.B. Acute viscerotropic disease following vaccination against yellow fever. Trans R Soc Trop Med Hyg 2007, 101(10):967-971.
7. Whittembury A., Ramirez G., Hernández H., Ropero A.M., Waterman S., Ticona M., et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 2009, 27(43):5974-5981.
8. Monath T.P. Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978) United States. Am J Trop Med Hyg 2010, 82(5):919-921.
9. Engel A.R., Vasconcelos P.F.C., McArthur M.A., Barrett A.D.T. Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. Vaccine 2006, 24(15):2803-2809.
10. Lindsey N.P., Schroeder B.A., Miller E.R., Braun M.M., Hinckley A.F., Marano N., et al. Adverse event reports following yellow fever vaccination. Vaccine 2008, 26(48):6077-6082.
11. Fitzner J., Coulibaly D., Kouadio D.E., Yavo J.C., Loukou Y.G., Koudou P.O., et al. Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan Ivory Coast. Vaccine 2004, 23(2):156-162.
12. Alexander L.N., Seward J.F., Santibanez T.A., Pallansch M.A., Kew O.M., Prevots D.R., et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 2004, 292(14):1696-1701.
13. Kelso J.M., Mootrey G.T., Tsai T.F. Anaphylaxis from yellow fever vaccine. J Allergy Clin Immunol 1999, 103(4):698-701.
14. Guimard T., Minjolle S., Polard E., Fily F., Zeller H., Michelet C., et al. Short report: incidence of yellow fever vaccine-associated neurotropic disease. Am J Trop Med Hyg 2009, 81(6):1141-1143.
15. Monath T.P., Cetron M.S. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis 2002, 34(10):1369-1378.
16. Transfusion-related transmission of yellow fever vaccine virus-California, 2009. Morb Mortal Wkly Rep 2010, 59(2):34-37.
17. Transmission of yellow fever vaccine virus through breast-feeding-Brazil, 2009. Morb Mortal Wkly Rep 2010, 59(5):130-132.
18. Tsai T.F., Paul R., Lynberg M.C., Letson G.W. Congenital yellow fever virus infection after immunization in pregnancy. J Infect Dis 1993, 168(6):1520-1523.
19. Guy B., Guirakhoo F., Barban V., Higgs S., Monath T.P., Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue West Nile and Japanese encephalitis viruses. Vaccine 2010, 28(3):632-649.
20. Hindle E. A yellow fever vaccine. Br Med J 1928, 1(3518):976-977.
21. Gaspar L.P., Mendes Y.S., Yamamura A.M.Y., Almeida L.F.C., Caride E., Gonçalves R.B., et al. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development. J Virol Methods 2008, 150(1-2):57-62.
22. Monath T.P., Lee C.K., Julander J.G., Brown A., Beasley D.W., Watts D.M., et al. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine 2010, 28(22):3827-3840.
23. Minor P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 2009, 27(20):2649-2652.
24. John J. Role of injectable and oral polio vaccines in polio eradication. Expert Rev Vaccines 2009, 8(1):5-8.
25. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997, 46(RR-3):1-25.
26. Update: outbreak of poliomyelitis-Dominican Republic and Haiti, 2000-2001. MMWR Morb Mortal Wkly Rep 2001, 50(39):855-856.
27. Poland J.D., Calisher C.H., Monath T.P., Downs W.G., Murphy K. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 1981, 59(6):895-900.
28. Chaib E., de Oliveira M.C.F., Galvão F.H.F., Silva F.D., D'Albuquerque L.A.C., Massad E. Theoretical impact of an anti-HCV vaccine on the annual number of liver transplantation. Med Hypotheses 2010, 75(3):324-327.
29. Bauch C.T., Li M., Chapman G., Galvani A.P. Adherence to cervical screening in the era of human papillomavirus vaccination: how low is too low?. Lancet Infect Dis 2010, 10(2):133-137.
30. Ziv E., Daley C.L., Blower S. Potential public health impact of new tuberculosis vaccines. Emerging Infect Dis 2004, 10(9):1529-1535.
31. Massad E., Coutinho F.A.B., Burattini M.N., Lopez L.F., Struchiner C.J. Yellow fever vaccination: how much is enough?. Vaccine 2005, 23(30):3908-3914.
32. Douce R.W., Freire D., Tello B., Vásquez G.A. A case of yellow fever vaccine-associated viscerotropic disease in Ecuador. Am J Trop Med Hyg 2010, 82(4):740-742.
33. Staples J.E., Gershman M., Fischer M. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010, 59(RR-7):1-27.